JOP20230107A1 - مشتقات سيكلو بنتا ثيوفين كربوكساميد كمضادات مستقبل عامل تنشيط الصفائح الدموية - Google Patents

مشتقات سيكلو بنتا ثيوفين كربوكساميد كمضادات مستقبل عامل تنشيط الصفائح الدموية

Info

Publication number
JOP20230107A1
JOP20230107A1 JOJO/P/2023/0107A JOP20230107A JOP20230107A1 JO P20230107 A1 JOP20230107 A1 JO P20230107A1 JO P20230107 A JOP20230107 A JO P20230107A JO P20230107 A1 JOP20230107 A1 JO P20230107A1
Authority
JO
Jordan
Prior art keywords
cyclopentathiophene
platelet
factor receptor
activating factor
receptor antagonists
Prior art date
Application number
JOJO/P/2023/0107A
Other languages
Arabic (ar)
English (en)
Inventor
Matthias Eckhardt
Juergen Prestle
Christofer Siegfried Tautermann
Leo Thomas
Ferenc Kontes
Dieter Wiedenmayer
Marina Kristina Willwacher
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of JOP20230107A1 publication Critical patent/JOP20230107A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
JOJO/P/2023/0107A 2020-11-16 2023-05-16 مشتقات سيكلو بنتا ثيوفين كربوكساميد كمضادات مستقبل عامل تنشيط الصفائح الدموية JOP20230107A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207719 2020-11-16
PCT/EP2021/081459 WO2022101377A1 (en) 2020-11-16 2021-11-12 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Publications (1)

Publication Number Publication Date
JOP20230107A1 true JOP20230107A1 (ar) 2023-05-16

Family

ID=73543025

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0107A JOP20230107A1 (ar) 2020-11-16 2023-05-16 مشتقات سيكلو بنتا ثيوفين كربوكساميد كمضادات مستقبل عامل تنشيط الصفائح الدموية

Country Status (20)

Country Link
US (2) US11766443B2 (enExample)
EP (1) EP4244229A1 (enExample)
JP (3) JP7465368B2 (enExample)
KR (1) KR20230109692A (enExample)
CN (2) CN116745300A (enExample)
AR (1) AR124070A1 (enExample)
AU (1) AU2021379248A1 (enExample)
CA (1) CA3200710A1 (enExample)
CL (2) CL2023001361A1 (enExample)
CO (1) CO2023005894A2 (enExample)
CR (2) CR20230211A (enExample)
DO (1) DOP2023000090A (enExample)
EC (1) ECSP23036210A (enExample)
IL (1) IL302769A (enExample)
JO (1) JOP20230107A1 (enExample)
MX (1) MX2023005678A (enExample)
PE (1) PE20231855A1 (enExample)
SA (1) SA523440809B1 (enExample)
TW (1) TWI913356B (enExample)
WO (1) WO2022101377A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
DD265405A5 (de) * 1986-01-21 1989-03-01 Boehringer Ingelheim Kg,De Neue thieno-1,4-diazepine
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
JP2959598B2 (ja) 1990-10-12 1999-10-06 吉富製薬株式会社 光学活性なチエノトリアゾロジアゼピン化合物
CN1033327C (zh) 1991-04-23 1996-11-20 东丽株式会社 三环三唑并衍生物的制造方法
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
US7749996B2 (en) 2006-11-20 2010-07-06 Alantos Pharmaceutical Holdings, Inc. Heterotricyclic metalloprotease inhibitors

Also Published As

Publication number Publication date
US20220160725A1 (en) 2022-05-26
CL2024000317A1 (es) 2024-07-12
AU2021379248A1 (en) 2023-06-22
TW202237620A (zh) 2022-10-01
CN117624188B (zh) 2026-08-07
JP7465368B2 (ja) 2024-04-10
CN117624188A (zh) 2024-03-01
PE20231855A1 (es) 2023-11-21
DOP2023000090A (es) 2023-06-15
JP7810743B2 (ja) 2026-02-03
CA3200710A1 (en) 2022-05-19
CO2023005894A2 (es) 2023-05-29
EP4244229A1 (en) 2023-09-20
CN116745300A (zh) 2023-09-12
JP2026090284A (ja) 2026-06-02
AU2021379248A9 (en) 2024-10-10
US11766443B2 (en) 2023-09-26
JP2023521200A (ja) 2023-05-23
ECSP23036210A (es) 2023-06-30
IL302769A (en) 2023-07-01
CR20230211A (es) 2023-07-13
SA523440809B1 (ar) 2024-10-08
WO2022101377A1 (en) 2022-05-19
US20230355638A1 (en) 2023-11-09
KR20230109692A (ko) 2023-07-20
TWI913356B (zh) 2026-02-01
CL2023001361A1 (es) 2023-11-03
MX2023005678A (es) 2023-05-26
CR20260053A (es) 2026-03-24
JP2024099528A (ja) 2024-07-25
AR124070A1 (es) 2023-02-08

Similar Documents

Publication Publication Date Title
SA523440916B1 (ar) Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات
MX2023007192A (es) Inhibidores de prmt5.
JOP20210097B1 (ar) مركبات 2-أمينو-n-أريل غير متجانس-نيكوتيناميد كمثبطات nav1.8
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022005399A (es) Compuestos.
JOP20230277A1 (ar) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض
MX386542B (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
EA202191498A1 (ru) 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
MX2020007265A (es) Derivados de rapamicina.
MX387394B (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
PA8845601A1 (es) Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1)
SA523451700B1 (ar) (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان
DE602005016261D1 (de) Substituierte arylaminderivate und verwendungsverfahren
SA522441554B1 (ar) Ripk1 مركبات أيزوكسازوليدين كمثبطات واستخدامها
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
MX2022013745A (es) Derivados de n-(piperidin-4-il)benzamida de accion luminal.
PH12021550549A1 (en) Dp antagonist
JOP20230275A1 (ar) معدلات trex1
MX2021015319A (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos.
EA202190322A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
EA202092763A1 (ru) Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных
ATE467636T1 (de) Pyrazoloä3 , 4-düazepinderivate als histamin-h3- antagonisten